Nymox Announces US NDA for Fexapotide for BPH

Nymox Pharmaceutical (NASDAQ:NYMX) announced that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.

As quoted in the press release:

The full results of the Company’s Phase 3 US trials were recently published in World Journal of Urology. World Journal of Urology is the Official Journal of the Urological Research Society and is also the Official Journal of the International Society of Urology.

Click here to read the full press release.